Loss of SMAD4 expression (cytoplasmic or nuclear) was associated with higher tumor SBR grade (p = 0.004) and more ER negativity (p = 0.02), while the nuclear localization of SMAD4 was not associated with any of the clinico-pathological parameters. Here, ESR1 is linked to neoplasm.